STOCK TITAN

NovoCure (NASDAQ: NVCR) director granted RSUs and options in 2026 award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NovoCure Ltd director Kristin Stafford received new equity awards. She was granted 11,610 ordinary shares in the form of restricted stock units at no cash cost, increasing her direct holdings to 22,934 ordinary shares.

She also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share. According to the award terms, the restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders. The options are scheduled to vest and become fully exercisable on the same timetable.

Positive

  • None.

Negative

  • None.
Insider Stafford Kristin
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 16,999 $0.00 --
Grant/Award Ordinary Shares 11,610 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 16,999 shares (Direct, null); Ordinary Shares — 22,934 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
RSU grant 11,610 shares Restricted stock units granted June 3, 2026
Shares held after grant 22,934 shares Direct ordinary shares following RSU grant
Stock options granted 16,999 options Options on ordinary shares granted June 3, 2026
Option exercise price $16.15 per share Exercise price for 16,999 options
RSU vesting trigger First anniversary / pre-2027 AGM RSUs vest 100% on earlier of these dates
Option expiration June 3, 2036 Expiration date for 16,999 stock options
restricted stock units financial
"Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"Stock Option (Right to Buy)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "16.1500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"scheduled to vest 100% on the earlier of the following dates"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual general meeting of shareholders financial
"the day immediately preceding the Company's 2027 annual general meeting of shareholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stafford Kristin

(Last)(First)(Middle)
C/O NOVOCURE INC.
1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)
WAYNE PENNSYLVANIA 19087

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)06/03/2026A11,610A$0.0022,934D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$16.1506/03/2026A16,99906/03/2027(2)06/03/2036Ordinary Shares16,999$0.0016,999D
Explanation of Responses:
1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Remarks:
Steven Robbins, as attorney in fact for Stafford, Kristin06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did NovoCure (NVCR) director Kristin Stafford report?

Kristin Stafford reported equity compensation grants, not market trades. She received 11,610 ordinary shares as restricted stock units and stock options for 16,999 ordinary shares, all awarded on June 3, 2026, with no cash purchase involved.

How many NovoCure (NVCR) shares does Kristin Stafford hold after the Form 4?

After the grant, Kristin Stafford directly holds 22,934 NovoCure ordinary shares. This figure includes the 11,610 restricted stock units granted on June 3, 2026, which are scheduled to vest in full on the disclosed vesting timetable.

What are the key terms of Kristin Stafford’s NovoCure stock options?

Stafford received options for 16,999 ordinary shares with a $16.15 exercise price. These options are scheduled to fully vest and become exercisable on the earlier of the first anniversary of the June 3, 2026 grant or the day before NovoCure’s 2027 annual general meeting.

When do Kristin Stafford’s NovoCure restricted stock units vest?

The 11,610 restricted stock units are scheduled to vest 100% on the earlier of two dates: the first anniversary of the June 3, 2026 grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders, according to the award terms.

Did Kristin Stafford buy or sell NovoCure (NVCR) shares on the market?

The Form 4 shows compensation-related acquisitions, not open-market trades. Stafford received restricted stock units and stock options as awards, each reported with transaction code “A” for grant or award, and no shares were reported as sold or purchased in the market.